Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Edmund J. Lewis, M.D., Lawrence G. Hunsicker, M.D., William R. Clarke, Ph.D., Tomas Berl, M.D., Marc A. Pohl, M.D., Julia B. Lewis, M.D., Eberhard Ritz, M.D., Robert C. Atkins, M.D., Richard Rohde, B.S., and Itamar Raz, M.D., for the Collaborative Study G
N Engl J Med. 2001 Sep 20;345(12):851-60
Google Plus
LinkedIn

Comments (2)

  1. Joel Topf

When this was published there were two areas of controversy. The first was that Barry Brenner, who was running the RENALL Trial simultaneously, shut down his trial after the HOPE trial was published because the DSMB thought that it was not...

When this was published there were two areas of controversy. The first was that Barry Brenner, who was running the RENALL Trial simultaneously, shut down his trial after the HOPE trial was published because the DSMB thought that it was not ethical to withhold ACEi/RAAS from people. This left Lewis and his team looking like monsters for continuing the trial.

The second controversy was the third arm of the trial. Irbesartan, okay. Placebo, okay. Amlodipine...really? How much better would the trial have been if it proved that both ARBs and ACEi were protective in type 2 diabetes. As it stood we only got half the information we wanted. Everyone assumed that the renal protection would extend over both classes but for years ACEi lacked the Grade A evidence found with ARB in type 2 DM. And if not the ACEi, how about a non-dihydropyrisdine calcium channel blocker that have been shown to reduce proteinuria?

All and all small blemishes to one of the landmark clinical trials in diabetic nephropathy.

Read More
  Attachments
 
  1. Dr. Jordan Weinstein

Interesting points Joel.

Regarding non-dihdropyridine CCBs, this is a still a relatively unanswered question whether they offer specific advantages over DHP-CCBs. At one time, I heard Bayer (promoting Adalat XL at the time) was considering a...

Interesting points Joel.

Regarding non-dihdropyridine CCBs, this is a still a relatively unanswered question whether they offer specific advantages over DHP-CCBs. At one time, I heard Bayer (promoting Adalat XL at the time) was considering a head-to-head trial with diltiazem XC. But of course, it never happened and so the theory never progressed beyond George Bakris' original work (a good article to add this repository). The apparent advantage of DHPs over non-DHPs for blood pressure potency also didn't help the cause of non-DHPs.

Jordan

Read More
  Attachments
 
There are no comments posted here yet

Leave your comments

Posting comment as a guest. Sign up or login to your account.
Attachments (0 / 3)
Share Your Location
Suggest an Article or Abstract

For suggested articles, Simply enter an article's PubMed ID number and our reviewers will consider the article for addition to the archive. Otherwise, attach a PDF below. You may also submit a visual abstract for consideration

Or
Add files